Louise Chen
Stock Analyst at Scotiabank
(2.70)
# 1,884
Out of 5,245 analysts
294
Total ratings
47.33%
Success rate
3.22%
Average return
Main Sectors:
Stocks Rated by Louise Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEVA Teva Pharmaceutical Industries | Maintains: Sector Outperform | $35 → $40 | $34.07 | +17.41% | 5 | Jan 29, 2026 | |
| JNJ Johnson & Johnson | Maintains: Sector Outperform | $230 → $265 | $234.34 | +13.08% | 41 | Jan 22, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Sector Perform | $53 → $60 | $59.46 | +0.91% | 2 | Jan 9, 2026 | |
| MRK Merck & Co. | Maintains: Sector Outperform | $105 → $120 | $122.41 | -1.97% | 26 | Dec 4, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Sector Perform | $650 → $770 | $638.88 | +20.52% | 2 | Nov 24, 2025 | |
| SRPT Sarepta Therapeutics | Upgrades: Sector Outperform | $80 | $16.80 | +376.19% | 3 | Jun 6, 2025 | |
| ACRS Aclaris Therapeutics | Maintains: Sector Outperform | $15 → $9 | $4.52 | +99.12% | 6 | May 9, 2025 | |
| EWTX Edgewise Therapeutics | Downgrades: Sector Perform | $50 → $14 | $32.70 | -57.19% | 2 | Apr 3, 2025 | |
| GANX Gain Therapeutics | Initiates: Sector Outperform | $12 | $1.78 | +574.16% | 1 | Mar 7, 2025 | |
| INVA Innoviva | Initiates: Sector Outperform | $55 | $22.46 | +144.88% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Perform | $55 | $68.81 | -20.07% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $15 | $3.98 | +276.88% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $113.99 | -56.14% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $15 | $6.11 | +145.50% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $17 | $32.67 | -47.96% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $70 | $13.07 | +435.58% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $17.37 | +187.85% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $30 | $7.94 | +277.83% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $55 | $18.62 | +195.46% | 8 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.76 | - | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $160 | $44.96 | +255.87% | 20 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $47.30 | - | 6 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $240 | $215.70 | +11.27% | 6 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $45 | $25.90 | +73.75% | 31 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $10.03 | - | 5 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $29.96 | - | 9 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $885 | $1,065.00 | -16.90% | 45 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.09 | - | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $34.15 | - | 10 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $15.20 | - | 6 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.96 | - | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $11.86 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $14.43 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.20 | - | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.7313 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $2.96 | +2,095.95% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $2.35 | +112.77% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $11.99 | +317.01% | 3 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $20.86 | +139.69% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $2.12 | +135.85% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $9 | $0.6714 | +1,240.48% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $59,062,500 | $2.91 | +2,029,639,075.26% | 1 | Jul 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $258 | $232.00 | +11.21% | 1 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $0.8588 | +5,722.08% | 2 | Jul 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.27 | +1,474.80% | 2 | Aug 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $5.96 | +655.03% | 1 | Jun 22, 2017 |
Teva Pharmaceutical Industries
Jan 29, 2026
Maintains: Sector Outperform
Price Target: $35 → $40
Current: $34.07
Upside: +17.41%
Johnson & Johnson
Jan 22, 2026
Maintains: Sector Outperform
Price Target: $230 → $265
Current: $234.34
Upside: +13.08%
Bristol-Myers Squibb Company
Jan 9, 2026
Maintains: Sector Perform
Price Target: $53 → $60
Current: $59.46
Upside: +0.91%
Merck & Co.
Dec 4, 2025
Maintains: Sector Outperform
Price Target: $105 → $120
Current: $122.41
Upside: -1.97%
Regeneron Pharmaceuticals
Nov 24, 2025
Maintains: Sector Perform
Price Target: $650 → $770
Current: $638.88
Upside: +20.52%
Sarepta Therapeutics
Jun 6, 2025
Upgrades: Sector Outperform
Price Target: $80
Current: $16.80
Upside: +376.19%
Aclaris Therapeutics
May 9, 2025
Maintains: Sector Outperform
Price Target: $15 → $9
Current: $4.52
Upside: +99.12%
Edgewise Therapeutics
Apr 3, 2025
Downgrades: Sector Perform
Price Target: $50 → $14
Current: $32.70
Upside: -57.19%
Gain Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $12
Current: $1.78
Upside: +574.16%
Innoviva
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $22.46
Upside: +144.88%
Mar 7, 2025
Initiates: Sector Perform
Price Target: $55
Current: $68.81
Upside: -20.07%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $3.98
Upside: +276.88%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $113.99
Upside: -56.14%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $6.11
Upside: +145.50%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $17
Current: $32.67
Upside: -47.96%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $70
Current: $13.07
Upside: +435.58%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $17.37
Upside: +187.85%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $30
Current: $7.94
Upside: +277.83%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $18.62
Upside: +195.46%
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.76
Upside: -
Nov 6, 2024
Reiterates: Overweight
Price Target: $160
Current: $44.96
Upside: +255.87%
Nov 6, 2024
Reiterates: Overweight
Price Target: n/a
Current: $47.30
Upside: -
Oct 31, 2024
Maintains: Overweight
Price Target: $200 → $240
Current: $215.70
Upside: +11.27%
Oct 25, 2024
Reiterates: Overweight
Price Target: $45
Current: $25.90
Upside: +73.75%
Oct 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.03
Upside: -
Sep 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $29.96
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $885
Current: $1,065.00
Upside: -16.90%
Sep 16, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.09
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $34.15
Upside: -
Aug 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $15.20
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.96
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.86
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $14.43
Upside: -
May 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.20
Upside: -
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.7313
Upside: -
Jan 31, 2024
Reiterates: Overweight
Price Target: $65
Current: $2.96
Upside: +2,095.95%
Sep 13, 2023
Reiterates: Overweight
Price Target: $5
Current: $2.35
Upside: +112.77%
Sep 5, 2023
Reiterates: Overweight
Price Target: $50
Current: $11.99
Upside: +317.01%
Aug 22, 2023
Reiterates: Overweight
Price Target: $50
Current: $20.86
Upside: +139.69%
Aug 17, 2023
Reiterates: Neutral
Price Target: $5
Current: $2.12
Upside: +135.85%
May 12, 2023
Maintains: Overweight
Price Target: $5 → $9
Current: $0.6714
Upside: +1,240.48%
Jul 7, 2021
Initiates: Overweight
Price Target: $59,062,500
Current: $2.91
Upside: +2,029,639,075.26%
Mar 27, 2020
Maintains: Neutral
Price Target: $240 → $258
Current: $232.00
Upside: +11.21%
Jul 19, 2018
Maintains: Overweight
Price Target: $40 → $50
Current: $0.8588
Upside: +5,722.08%
Aug 18, 2017
Initiates: Overweight
Price Target: $20
Current: $1.27
Upside: +1,474.80%
Jun 22, 2017
Initiates: Overweight
Price Target: $45
Current: $5.96
Upside: +655.03%